Jerry J. Jaboin, MD, PhD

Jerry J. Jaboin, MD, PhD

Faculty Rank:

Vice-Chair for Clinical Affairs


Radiation Medicine


Central nervous system (brain), Pediatric oncology, Gynecologic oncology


M.D., Howard University College of Medicine 

Ph.D., Howard University College of Medicine


Radiation Oncology, Vanderbilt University School of Medicine (Holman Research Track Pathway)


American Board of Radiology/Radiation Oncology


Jerry J Jaboin:


Dr. Jaboin comments on lifespan of linear accelerators


New Publication from Drs. Jerry Jaboin, Shearwood McClelland III and Charles Thompson

Jehan Yahya will be presenting 2 papers at the  2018 Gastrointestinal Cancers Symposium

New published article on palliative care model

Dr. Jerry J. Jaboin interviewed by KATU to provide perspective on Sen. John McCain's diagnosis

Drs. Jerry Jaboin & CR Thomas co-authors of disparities research in radiation oncology care

Dr. Jaboin's research team publishes acoustic neuroma population database analysis

NDRG4 is a novel oncogenic protein and p53 associated regulator of apoptosis in malignant meningioma cells

A novel component from citrus, ginger, and mushroom family exhibits antitumor activity on human meningioma cells through suppressing the Wnt/β-catenin signaling pathway.

A retrospective analysis of survival and prognostic factors after stereotactic radiosurgery for aggressive meningiomas.

Autotaxin Inhibition with PF-8380 Enhances the Radiosensitivity of Human and Murine Glioblastoma Cell Lines

Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.

Survival following gamma knife radiosurgery for brain metastasis from breast cancer

Segmentation editing improves efficiency while reducing inter-expert variation and maintaining accuracy for normal brain tissues in the presence of space-occupying lesions.

High-throughput identification of putative receptors for cancer-binding peptides using biopanning and microarray analysis

Recurrent adult-onset hypophyseal Langerhans cell histiocytosis after radiotherapy: a case report.

Trigeminal neuralgia post-styloidectomy in Eagle syndrome: a case report.

NDRG4, the N-Myc downstream regulated gene, is important for cell survival, tumor invasion and angiogenesis in meningiomas

GSK-3β: A Bifunctional Role in Cell Death Pathways

Kinomic profiling approach identifies Trk as a novel radiation modulator

Comparison of manual and automatic segmentation methods for brain structures in the presence of space-occupying lesions: a multi-expert study

Increase in mastectomies performed in patients in the community setting undergoing MRI

The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer.

The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer.

Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer

Using in vivo biopanning for the development of radiation-guided drug delivery systems.

No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.

Regulated cell death pathways: new twists in modulation of BCL2 family function.

Autophagy in lung cancer

Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer.

The role of mTOR inhibition in augmenting radiation induced autophagy.

Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death

The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).

Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma

Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis.

Links of Interest